Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer — Stella

Recruiting

Back to HER2-positive Breast Cancer trials

Trial locations(1 site)

China

Peking University People's Hospital, Beijing, Beijing Municipality

Key details

Sponsor

Shu Wang

Enrollment target

~2,806 participants

Started

January 2019

Primary completion

December 2031

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov